MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-25-2026
BioLineRx Ltd. ROCE Ratio 2011-2026 | BLRX
Annual ROCE Ratio BioLineRx Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | -104.07 | -67.58 | -51.75 | -46.53 | -46.81 | -33.63 | -47.65 | -103.99 | -122.1 | -68.24 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -33.63 | -122.1 | -69.23 |
Quarterly ROCE Ratio BioLineRx Ltd.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -8.0 | -16.0 | -16.0 | -8.0 | -21.49 | -26.98 | -26.98 | -13.49 | -25.62 | -24.26 | -24.26 | -12.13 | -24.35 | -24.44 | -24.44 | -12.22 | -21.26 | -18.09 | -18.09 | -9.04 | -9.04 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.0 | -26.98 | -18.29 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 9.33 | 1.41 % | $ 603 M |  USA |
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
31.5 | $ 22.38 | 0.81 % | $ 3.71 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
-3.51 | $ 28.15 | 1.04 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
7.15 | $ 8.22 | 3.92 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
20.45 | $ 30.95 | -0.34 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
4.28 | $ 8.43 | -0.12 % | $ 76.1 M | USA |
 |
InflaRx N.V.
IFRX
|
-24.77 | $ 1.97 | -0.51 % | $ 152 M | Germany |
 |
Incyte Corporation
INCY
|
29.32 | $ 98.55 | -0.55 % | $ 19.2 B | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 0.71 | 1.27 % | $ 1.74 M |  Canada |
 |
Innoviva
INVA
|
13.96 | $ 22.97 | -0.35 % | $ 1.55 B | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 104.02 | 2.41 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Jaguar Health
JAGX
|
245.65 | $ 7.34 | -6.79 % | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
4132.68 | $ 26.68 | 0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
0.41 | $ 1.45 | -2.68 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
10.36 | $ 8.16 | 0.68 % | $ 260 M |  Israel |
 |
Krystal Biotech
KRYS
|
13.23 | $ 260.24 | 0.11 % | $ 7.53 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-45.76 | $ 13.58 | 9.34 % | $ 1.8 B |  Australia |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-116.14 | - | - | $ 28.6 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
-2.72 | $ 220.06 | -2.13 % | $ 4.02 B | USA |
 |
AlloVir
ALVR
|
-58.56 | - | 4.14 % | $ 49.1 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-146.69 | $ 2.94 | -1.67 % | $ 4.84 M | Israel |
 |
Liquidia Corporation
LQDA
|
-114.81 | $ 38.41 | 0.67 % | $ 3.31 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-51.5 | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
394.73 | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-46.69 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.08 | 0.62 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
-664.7 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
123.77 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 23.15 | 3.49 % | $ 2.95 B | USA |